Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax® in healthy vaccinia-naive adults

Vaccine

Volumn 27, Issue 10, 2009, Pages 1637-1644

  Frey, Sharon E ^a   Newman, Frances K ^a   Kennedy, Jeffrey S ^b   Ennis, Francis ^b   Abate, Getahun ^a   Hoft, Daniel F ^a   Monath, Thomas P ^c  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c Acambis   (United States)

Author keywords

ACAM1000; ACAM2000; Cell mediated immunity; Dryvax ; Gamma delta T cells; Neutralizing antibody

Indexed keywords

NEUTRALIZING ANTIBODY; SMALLPOX VACCINE;

ADULT; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HOT FLUSH; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; LYMPH NODE PAIN; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALAISE; MALE; MEMORY T LYMPHOCYTE; MYALGIA; NAUSEA; NEUTROPHIL COUNT; NOSE CONGESTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINORRHEA; RIGOR; SIDE EFFECT; SKIN MANIFESTATION; ST SEGMENT ELEVATION; VACCINATION; VACCINIA; VIREMIA; VIRUS SHEDDING; VIRUS STRAIN;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; MALE; NEUTRALIZATION TESTS; SAFETY; SKIN; SMALLPOX VACCINE; T-LYMPHOCYTES; VACCINIA VIRUS; YOUNG ADULT;

EID: 60349109989     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.11.079     Document Type: Article

References (20)

1. Demkowicz Jr. W.E., Littaua R.A., Wang J., and Ennis F.A. Human cytotoxic T-cell memory: long-lived responses to vaccinia virus [Journal Article. Research Support, Non-U.S. Gov't. Research Support, U.S. Gov't, P.H.S.]. J Virol 70 4 (1996) 2627-2631
2. Frey S.E., Newman F.K., Yan L., Lottenbach K.R., and Belshe R.B. Response to smallpox vaccine in persons immunized in the distant past. JAMA 289 24 (2003) 3295-3299
3. Hammarlund E., Lewis M.W., Hansen S.G., Strelow L.I., Nelson J.A., Sexton G.J., et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 9 9 (2003) 1131-1137
4. Weltzin R., Liu J., Pugachev K.V., Myers G., Coughlin B., Nichols R., et al. Clonal cell culture-grown vaccinia virus (New York City Board of Health strain) as a second-generation smallpox vaccine. Nat Med 9 9 (2003) 1125-1130
5. Monath T.P., Caldwell J.R., Mundt W., Fusco J., Johnson C.S., Buller M., et al. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)-a second-generation smallpox vaccine for biological defense. Internat J Infect Dis 8 Suppl 2 (2004) S31-44
6. Advisory Committee on Immunization Practices Membership List, March 2001. Vaccinia (Smallpox) Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP) 2001. MMWR Recommendations and Reports June 22, 2001;50(RR10):1-2.
7. Wharton M., Strikas R.A., Harpaz R., Rotz L.D., Schwartz B., Casey C.G., et al. Recommendations for using smallpox vaccine in a pre-event vaccination program supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR 52 RR07 (2003) 1-16
8. ®) virus vaccine. J Infect Dis 187 8 (2003) 1319-1322
9. Marriott K.A., Parkinson C.V., Morefield S.I., Davenport R., Nichols R., and Monath T.P. Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge. Vaccine 26 4 (2008) 581-588
10. Demkowicz W.E., and Ennis F.A. Vaccinia virus-specific CD8+ cytotoxic T lymphocytes in humans. J Virol 67 3 (1993) 1538-1544
11. Kennedy J.S., Frey S.E., Yan L., Rothman A.L., Cruz J., Newman F.K., et al. Induction of human T-cell-mediated immune responses after primary and secondary smallpox vaccination. J Infect Dis 190 7 (2004) 1286-1294
12. Frey S.E., Newman F.K., Cruz J., Shelton B., Tennant J.M., Polach T., et al. Dose-related effects of smallpox vaccine. New Engl J Med 346 17 (2002) 1275-1280
13. Pross H.F., Baines M.G., Rubin P., Shragge P., and Patterson M.S. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol 1 1 (1981) 51-63
14. Ennis F.A., Cruz J., Demkowitz W.E., Rothman A.L., and McClain D.J. Primary induction of human CD8+ cytotoxic T lymphocytes and interferon γ-producing T cells after smallpox vaccination. J Infect Dis 185 11 (2002) 1657-1659 8
15. Littaua R.A., Takeda A., Cruz J., and Ennis F.A. Vaccinia virus-specific human CD4+ cytotoxic T-lymphocyte clones. J Virol 66 4 (1992) 2274-2280
16. Abate G., Eslick J., Newman F.K., Frey S.E., Belshe R.B., Monath T.P., et al. Flow-cytometric detection of vaccinia-induced memory effector CD4(+), CD8(+), and gamma delta TCR(+) T cells capable of antigen-specific expansion and effector functions. J Infect Dis 192 8 (2005) 1362-1371
17. Newman F.K., Frey S.E., Blevins T.P., Mandava M., Bonifacio Jr. A., Yan L., et al. Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine. J Clin Microbiol 41 7 (2003) 3154-3157
18. Halsell J.S., Riddle J.R., Atwood J.E., Gardner P., Shope R., Poland G.A., et al. Myopericarditis following smallpox vaccination among vaccinia-naïve US military personnel. JAMA 289 24 (2003) 3283
19. Poland G.A., Grabenstein J.D., and Neff J.M. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine 23 (2005) 2078-2081
20. Morris L., José O., and Martinez A.V. Epidemiologic investigation of a smallpox outbreak in a town reported to be "100 per cent vaccinated". Am J Epidemiol 92 (1970) 294-300